A new study published in the November 2026 issue of the Journal of the National Comprehensive Cancer Network (JNCCN) reports that patients with advanced non-small cell lung cancer (NSCLC) live longer when they receive broad-based genomic sequencing before starting treatment. The research compares broad genomic testing—screening dozens or hundreds of genes at once—with more limited biomarker testing focused on one or two genes.
Both outlets describe the work as aligning with recommendations in the National Comprehensive Cancer Network (NCCN) Guidelines, which call for comprehensive biomarker testing prior to treatment in advanced lung cancer. While the scientific finding is the same across sources, the coverage emphasis differs slightly: Medical Xpress frames the study’s survival association and the broad-vs-limited testing contrast, while PR Newswire highlights the guideline-recommended testing approach and presents the information as a news announcement linked to the journal publication.
